公开(公告)号：EP2480531A1

公开(公告)日：2012-08-01

申请号：EP10757922.9

申请日：2010-09-21

申请人： ChemoCentryx, Inc.

发明人： CHARVAT, Trevor T. ,  CHU, Hiufung ,  KRASINSKI, Antoni ,  LANGE, Christopher W. ,  LELETI, Manmohan Reddy ,  POWERS, Jay P. ,  PUNNA, Sreenivas ,  SULLIVAN, Timothy J. ,  UNGASHE, Solomon

IPC分类号： C07D209/46 ,  C07D209/52 ,  C07D401/06 ,  C07D403/06 ,  C07D405/04 ,  C07D493/04 ,  C07D207/416 ,  A61K31/4025 ,  A61P29/00

CPC分类号： C07D207/277 ,  C07D207/416 ,  C07D209/46 ,  C07D209/52 ,  C07D401/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/04 ,  C07D413/06 ,  C07D491/048 ,  C07D491/052 ,  C07D493/04

摘要： Pyrrolidinone carboxamide compounds of formula (I) are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.

公开(公告)号：EP2046762B1

公开(公告)日：2011-02-16

申请号：EP07836049.2

申请日：2007-07-10

申请人： ChemoCentryx, Inc.

发明人： CHARVAT, Trevor, T. ,  HU, Cheng ,  MELIKIAN, Anita ,  NOVACK, Aaron ,  PENNELL, Andrew, M.K. ,  SULLIVAN, Edward, J. ,  TAN, Xuefei ,  THOMAS, William, D. ,  UNGASHE, Solomon ,  ZENG, Yibin ,  PUNNA, Sreenivas

IPC分类号： C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D413/04 ,  A61K31/41 ,  A61P29/00

CPC分类号： C07D401/04 ,  C07D249/08 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D413/04

摘要： Compounds (I) are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2 -mediated diseases, CCR9 -mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

公开(公告)号：EP1567486B1

公开(公告)日：2008-01-16

申请号：EP03816012.3

申请日：2003-11-18

申请人： ChemoCentryx, Inc.

发明人： UNGASHE, Solomon ,  WEI, Zheng ,  WRIGHT, J., J. ,  PENNELL, Andrew ,  PREMACK, Brett ,  SCHALL, Thomas, J.

IPC分类号： C07C311/21 ,  A61K31/18 ,  A61P29/00

CPC分类号： C07C311/29 ,  C07C311/21 ,  C07C311/46 ,  C07C317/14 ,  C07D213/26 ,  C07D213/50 ,  C07D213/70 ,  C07D213/74 ,  C07D213/84 ,  C07D213/89 ,  C07D241/12 ,  C07D413/12

摘要： Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

公开(公告)号：EP2175859B1

公开(公告)日：2012-03-07

申请号：EP08781709.4

申请日：2008-07-11

申请人： ChemoCentryx, Inc.

发明人： KRASINSKI, Antoni ,  PUNNA, Sreenivas ,  UNGASHE, Solomon ,  WANG, Qiang ,  ZENG, Yibin

IPC分类号： A61K31/519 ,  C07D473/00 ,  C07D487/04 ,  A61P29/00

CPC分类号： C07D487/04 ,  C07D213/79 ,  C07D213/81 ,  C07D213/84 ,  C07D471/04 ,  C07D471/12 ,  C07D473/00

摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;

摘要翻译： 提供了作为CCR2受体的有效拮抗剂的化合物。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法和用于鉴定CCR2拮抗剂的测定中的对照。

公开(公告)号：EP2049515A2

公开(公告)日：2009-04-22

申请号：EP07810331.4

申请日：2007-07-10

申请人： ChemoCentryx, Inc.

发明人： CHARVAT, Trevor, T. ,  HU, Cheng ,  JIN, Jeff ,  LI, Yandong ,  MELIKIAN, Anita ,  PENNELL, Andrew, M.K. ,  PUNNA, Sreenivas ,  UNGASHE, Solomon ,  ZENG, Yibin

IPC分类号： C07D401/04 ,  C07D401/14 ,  A61K31/4439 ,  A61P9/10

CPC分类号： C07D401/14

摘要： A compound of the formula (I) for treating a CCR2-mediated condition or disease or a CCR9-mediated condition or disease, where the disease or condition is selected from the group consisting of atherosclerosis, restenosis, multiple sclerosis, inflammatory bowel disease, renal fibrosis, rheumatoid arthritis, obesity, diabetes, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, idiopathic pneumonia syndrome, pulmonary fibrosis, transplantation rejection, graft- versus- host disease, cancer, and neuropathic pain wherein Ar is selected from the group consisting of substituted or unsubsituted Cβ-io aryl and substituted or unsubstituted 5- to 10- membered heteroaryl; Y1 to Y4 are selected from the group consisting of -CR3a- to -CR3d-, -N-, and -N+(O)-, wherein at least one of Y1, Y2, Y3, or Y4 is -N-.

公开(公告)号：EP2046762A2

公开(公告)日：2009-04-15

申请号：EP07836049.2

申请日：2007-07-10

申请人： ChemoCentryx, Inc.

发明人： CHARVAT, Trevor, T. ,  HU, Cheng ,  MELIKIAN, Anita ,  NOVACK, Aaron ,  PENNELL, Andrew, M.K. ,  SULLIVAN, Edward, J. ,  TAN, Xuefei ,  THOMAS, William, D. ,  UNGASHE, Solomon ,  ZENG, Yibin ,  PUNNA, Sreenivas

IPC分类号： C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D413/04 ,  A61K31/41 ,  A61P29/00

CPC分类号： C07D401/04 ,  C07D249/08 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D413/04

摘要： Compounds (I) are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2 -mediated diseases, CCR9 -mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.

摘要翻译： 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物（I）。 动物试验表明，这些化合物可用于治疗炎症，这是CCR2和CCR9的标志性疾病。 所述化合物通常为芳基磺酰胺衍生物并且可用于药物组合物，治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为鉴定CCR2拮抗剂的试验中的对照以及作为鉴定CCR9拮抗剂的试验中的对照 。

公开(公告)号：EP1748989A2

公开(公告)日：2007-02-07

申请号：EP05747905.7

申请日：2005-05-12

申请人： ChemoCentryx, Inc.

发明人： UNGASHE, Solomon ,  WRIGHT, John, Jessen ,  PENNELL, Andrew

IPC分类号： C07D233/54 ,  C07D405/04 ,  C07D257/04 ,  C07D213/87 ,  C07D213/53 ,  C07D217/14 ,  C07D471/06 ,  C07C311/29 ,  C07C311/21 ,  A61P29/00 ,  A61K31/18 ,  A61K31/435 ,  A61K31/41

CPC分类号： C07D233/64 ,  C07C311/21 ,  C07C311/29 ,  C07D213/53 ,  C07D213/89 ,  C07D217/14 ,  C07D257/04 ,  C07D405/04 ,  C07D471/04

摘要： The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.

公开(公告)号：EP2748146B1

公开(公告)日：2017-03-08

申请号：EP12741219.5

申请日：2012-07-20

申请人： ChemoCentryx, Inc.

发明人： PENNELL, Andrew, M.K. ,  UNGASHE, Solomon

IPC分类号： C07D213/89 ,  A61K31/4412 ,  A61P29/00

CPC分类号： C07D213/89

公开(公告)号：EP2170823B1

公开(公告)日：2014-08-06

申请号：EP08831941.3

申请日：2008-06-18

申请人： ChemoCentryx, Inc.

发明人： CHARVAT, Trevor, T. ,  HU, Cheng ,  MELIKIAN, Anita ,  NOVACK, Aaron ,  PENNELL, Andrew, M.K. ,  POWERS, Jay ,  PUNNA, Sreenivas ,  SULLIVAN, Edward, J. ,  THOMAS, William, D. ,  UNGASHE, Solomon ,  ZHANG, Penglie

IPC分类号： C07D209/08 ,  C07D231/12 ,  C07D231/14 ,  C07D231/16 ,  C07D231/56 ,  C07D233/61 ,  C07D235/08 ,  C07D249/06 ,  C07D249/18 ,  C07D401/04 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04

CPC分类号： C07D473/00 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/496 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  C07D209/08 ,  C07D231/12 ,  C07D231/14 ,  C07D231/16 ,  C07D231/56 ,  C07D233/61 ,  C07D235/06 ,  C07D235/08 ,  C07D249/06 ,  C07D249/18 ,  C07D401/04 ,  C07D401/14 ,  C07D403/06 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C12N2501/999

公开(公告)号：EP2748146A1

公开(公告)日：2014-07-02

申请号：EP12741219.5

申请日：2012-07-20

申请人： ChemoCentryx, Inc.

发明人： PENNELL, Andrew, M.K. ,  UNGASHE, Solomon

IPC分类号： C07D213/89 ,  A61K31/4412 ,  A61P29/00

CPC分类号： C07D213/89

摘要： A novel crystalline form of the sodium salt of 4-
tert -butyl-
N -[4-chloro-2-(1- oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same are disclosed. Processes for the preparation thereof and methods for use thereof are also disclosed.

摘要翻译： 公开了4-叔丁基-N- [4-氯-2-（1-氧基 - 吡啶-4-羰基） - 苯基] - 苯磺酰胺的钠盐的新结晶形式和含有该结晶形式的药物组合物。 还公开了其制备方法及其使用方法。